The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 125-141

  Mills, Gordon B ^a,b,c   Lu, Yiling ^a,b,c   Fang, Xianjun ^a,b,c   Wang, Hongwei ^a,b,c   Eder, Astrid ^a,b,c   Mao, Muling ^a,b,c   Swaby, Ramona ^a,b,c   Cheng, Kwai Wa ^a,b,c   Stokoe, David ^a,b,c   Siminovitch, Kathy ^a,b,c   Jaffe, Robert ^a,b,c   Gray, Joe ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; GENE PRODUCT; GROWTH FACTOR RECEPTOR; INTEGRIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN P21; RAC PROTEIN; RAF PROTEIN;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER INHIBITION; CELL PROLIFERATION; CONFERENCE PAPER; ENZYME REGULATION; GENE FUNCTION; GENE MUTATION; GENE TARGETING; HUMAN; NONHUMAN; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0035168724     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28554     Document Type: Conference Paper

References (110)

1. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease
2. PTEN, a putative protein Tyr phosphatase gene mutated in human brain, breast and prostate cancer
3. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
4. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein Tyr phosphatase regulated by transforming growth factor β
5. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling
6. MMAC1/PTEN: Mutations in primary tumor specimens and tumor cell lines
7. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas
8. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas
9. Infrequent genetic alterations of the PTEN/MMAC1 gene in Japanese patients with primary cancers of the breast, lung, pancreas, kidney, and ovary
10. Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers
11. Mutation analysis of the putative tumor suppression gene PTEN/MMAC1 in sporadic breast cancer
12. Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus
13. Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas
14. Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma
15. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype
16. PIK3CA is implicated as an oncogene in ovarian cancer
17. Signaling through the lipid products of phosphoinositide-3-OH kinase
18. Signalling through phosphoinositide 3-kinases: The lipids take centre stage
19. AKT/PKB and other D3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation
20. Oncogenes and signal transduction
21. Requirement for both Shc and phosphatidylinositol 3¢kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis
22. Transformation of chicken cells by the gene encoding the catalytic subunit of P13 kinase
23. The catalytic subunit of phosphoinositide 3-kinase: Requirements for oncogenicity
24. Role of phosphoinositide-3-OH kinase in Ras signaling
25. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase
26. Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo
27. Transforming activity and mitosis-related expression of the AKT2 oncogene: Evidence suggesting a link between cell cycle regulation and oncogenesis
28. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
29. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines
30. Germline mutations in PTEN are present in Bannayan-Zonana syndrome
31. The Cowden syndrome: A clinical and genetic study in 21 patients
32. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-kinase/AKT in breast cancer cells
33. BRCA1 inhibition of estrogen receptor signaling in transfected cells
34. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase
35. P13 kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance
36. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies
37. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors
38. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines
39. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas
40. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
41. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma
42. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation
43. Allelic imbalance and mutations of the PTEN gene in ovarian cancer
44. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies
45. Alterations in DNA methylation A fundamental aspect of neoplasia
46. Immunohisto-chemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast
47. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias
48. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation
49. Phosphorylation of the PTEN tail regulates protein stability and function
50. PTEN is essential for embryonic development and tumour suppression
51. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice
52. +/- mice
53. PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
54. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN
55. The tumor suppressor, PTEN/ MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
56. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function
57. PTEN Sometimes taking it off can be better than putting it on
58. Mutations of the human PTEN gene
59. Crystal structure of the PTEN tumor suppressor Implications for its phosphoinositide phosphatase activity and membrane association
60. Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor
61. The tumor-suppressor activity of PTEN is regulated by its carboxy-terminal region
62. Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations Differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase
63. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2
64. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase
65. Threonine phosphorylation of the MMAC1/PTEN PDZ binding domain both inhibits and stimulates PDZ binding
66. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits AKT activation and induces anoikis
67. PKB/akt activity is elevated in glioblastoma cells due to mutation of PTEN/MMAC1
68. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells
69. The PTEN/ MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
70. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN
71. PTEN transcriptionally modulates c-myc gene expression in human breast carcinoma cells and is involved in cell growth regulation
72. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway
73. PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death
74. Loss of PTEN facilitates HIF-1-mediated gene expression
75. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
76. Molecular genetic defects in endometriosis
77. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells
78. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer
79. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer
80. DNA copy number amplifications in human neoplasms Review of comparative genomic hybridization studies
81. Molecular definition of a small amplification domain within 3q26 in tumors of cervix, ovary, and lung
82. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix
83. PIK3CA as an oncogene in cervical cancer
84. Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas
85. Genetic imbalances with impact on survival in head and neck cancer patients
86. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor
87. Tcll enhances Akt kinase activity and mediates its nuclear translocation
88. The protooncogene TCL1 is an Akt kinase coactivator
89. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the P13-kinase-Akt pathway in human endothelial cells
90. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I
91. A function of phosphatidylinositol 3-kinase β (p85α-p110β) in fibroblasts during mitogenesis Requirement for insulin- and lysophosphatidic acid-mediated signal transduction
92. The P13-kinase isoforms p110α and p110β have differential roles in PDGF- and insulin-mediated signaling
93. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase
94. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha
95. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells
96. Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kγ
97. Regulation of the p85/p110 phosphatidylinositol 3′-kinase Stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit
98. Regulation of phosphatidylinositol 3′kinase by tyrosyl phosphoproteins
99. SHP-1 regulates LCK-induced phosphatidylinositol 3′ kinase phosphorylation and activity
100. Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation
101. Mechanism of protein kinase B activation by cyclic AMP-dependent protein kinase
102. The Ca-calmodulin-dependent protein kinase cascade
103. Modulation of akt kinase activity by binding to hsp90
104. Inhibition of growth factor-induced phosphorylation and activation of PKB/AKT by atypical protein kinase C in breast cancer cells
105. Aberrant subcellular localization of BRCA1 in breast cancer
106. Localization of BRCA1 protein at the cellular level
107. A nuclear function for the tumor suppressor BRCA1
108. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway
109. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
110. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3β